Is Nano-X Imaging (NASDAQ:NNOX) a buy in 2026?
Lean no. The Compass would trim Nano-X Imaging here, not add.
A cold-fusion bet on reinventing X-ray hardware that keeps burning cash while the commercial story slips year after year.
Where NNOX is headed
Picture Nano-X in late 2027. The Nanox.ARC has been FDA-cleared for years, a few hundred units sit in clinics across the US, Mexico, and parts of Europe, and the company has hit something like $40-60M in annual revenue. That sounds like progress until you look at the cost side. Gross margin is still negative or barely positive because each ARC unit ships with a service-and-cloud model that needs scan volume the installed base cannot yet generate. Operating losses are still running $60-80M a year, and the share count has crept higher again through another equity raise at a depressed price. This is the realistic destination, and it is a destination where the equity has been diluted to fund a science project that has not yet earned the right to call itself a business.
Read the full Compass Direction on NNOX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full NNOX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Nano-X Imaging (NASDAQ:NNOX) a buy in 2026?
Lean no. The Compass would trim Nano-X Imaging here, not add. A cold-fusion bet on reinventing X-ray hardware that keeps burning cash while the commercial story slips year after year.
What is NNOX's Compass Score?
Nano-X Imaging scores 58/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for NNOX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the NNOX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.